High expression of GEM and EDNRA is associated with metastasis and poor outcome in patients with advanced bladder cancer.

ABSTRACT:

Background

The standard treatment for non-metastatic muscle-invasive bladder cancer (stages T2-T4a) is radical cystectomy with lymphadenectomy. However, patients undergoing cystectomy show metastatic spread in 25% of cases and these patients will have limited benefit from surgery. Identification of patients with high risk of lymph node metastasis will help select patients that may benefit from neoadjuvant and/or adjuvant chemotherapy.

Methods

RNA was procured by laser micro dissection of primary bladder tumors and corresponding lymph node metastases for Affymetrix U133 Plus 2.0 Gene Chip expression profiling. A publically available dataset was used for identification of the best candidate markers, and these were validated using immunohistochemistry in an independent patient

SUBMITTER: Laurberg JR 

PROVIDER: S-EPMC4164753 | biostudies-literature | 2014 Aug

REPOSITORIES: biostudies-literature